Recent studies have demonstrated that aging or senescence constitutes a potential limitation to the ability of endothelial progenitor cells (EPCs) to sustain ischemic tissue repair. Excess amount of reactive oxygen species (ROS) is involved in senescence, causing defective neovascularization. Conversely, estrogens have been shown to accelerate recovery of the endothelium after vascular injury. Estrogen reduces EPC senescence through augmentation of telomerase activity. In addition, the inhibition of EPC senescence by estrogen in vitro may improve the functional activity of EPCs in a way that is important for potential cell therapy. This review describes current understanding of EPC senescence and the role of estrogen in preventing EPC senescence.
Introduction
The lower incidence of cardiovascular disease (CVD) in premenopausal women than in men may be attributable, at least in part, to estrogen [Dubey and Jackson, 2001; Mendelsohn and Karas, 1999; Nathan and Chaudhuri, 1997; Farhat et al. 1996 ]. Premenopausal women are at a lower risk for atherosclerosis and thus have a lower incidence of coronary heart disease and myocardial infarction than postmenopausal women or age-matched men. It has long been postulated that the concentration of circulating 17b-estradiol (E 2 ) plays an important role in the gender-specific cardioprotective effect; however, the underlying mechanism of action of E 2 remains a matter of debate. Relevant biological effects of estrogens are numerous and include, for example, an improvement in lipid and lipoprotein profiles and endothelium-dependent vasodilation triggered by E 2 at physiological concentration.
Age-associated changes in many aspects of cardiovascular function appear to contribute to this increased risk for CVD. These include (1) impairment of the regulation of vascular tone that is attributable, for example, to decreased itric oxide (NO) production and increased levels of angiotensin II (Ang II) and endothelin [Amrani et al. 1996];  (2) increased coagulation activity and decreased fibrinolytic capacity, leading to increased risk of coronary thrombosis [Hager et al. 1989; Bauer et al. 1987];  (3) dysregulated angiogenic repair mechanisms that are important for restoration of blood flow after ischemic injury; and (4) a decrease in the number and function of circulating endothelial progenitor cells (EPCs) [Heiss et al. 2005; Scheubel et al. 2003; Vasa et al. 2001a ]. Furthermore, cellular senescence resulting from accumulation of oxidative damage, telomere shortening and the loss of replicative ability in vascular cells also contributes to the progressive inability of the heart and vasculature to repair themselves after injury [Erusalimsky and Kurz, 2006] .
Based on recent studies, BM-derived EPCs seem to play an important contribution to estrogeninduced cardiac repair mechanism. Treatment with E 2 enhances the mobilization and proliferation of EPCs, accelerates re-endotheliazation and attenuates neointima formation after vascular injury in murine models [Stehlow et al. 2003; Iwakura et al. 2003 ]. E 2 also enhances recovery in murine myocardial infarction models by increasing EPC mobilization and incorporation at sites of ischemia, a mechanism involving estrogen receptors a and b (ERa, ERb) [Hamada et al. 2006; Iwakura et al. 2006 ]. In vitro, E 2 reduces EPC senescence by increasing telomerase activity [Imanishi et al. 2005a] . Taken together, these data suggest that, by positively regulating BM-derived EPC mobilization and function in cardiac repair mechanisms, E 2 certainly modulates biological processes involved in the functional organization of the stem cell niche. This review describes current understanding of EPC senescence and the role of estrogen in preventing EPC senescence.
Senescent bone marrow-derived EPCs and impairment of cardiovascular repair EPCs significantly contribute to adult vessel formation by physically incorporating into and promoting the growth of vessels through paracrine mechanisms [Lin et al. 2000; Asahara et al. 1997] . It is believed that the majority of EPCs originate from the bone marrow (BM). Their movement from the BM to the vascular endothelium can be divided into three stages Histov et al. 2003 ]. First, EPCs are mobilized or released from the BM into the systemic circulation in response to specific stimuli (mobilization): a number of cytokines and growth factors appear to promote this step. Subsequently, the cells appear to home preferentially to sites of tissue injury (homing). Finally, some EPCs are incorporated into new blood vessels formed by the extension of existing vessels (angiogenesis) or possibly formed in situ (vasculogenesis). E 2 stimulates migration and proliferation of the endothelium [Billon et al. 2008; Fontaine et al. 2006; Gargett et al. 2002] . This effect involves factors such as endothelial nitric oxide synthase (eNOS) activity, prostacyclin, endothelin, basic fibroblast growth factor (bFGF), and vascular endothelial growth factor receptor 2 (VEGF-R2) signaling. Estrogen also stimulates the recruitment of EPCs, which in experimental and emerging clinical studies, appear to be important effectors of endothelial repair [Besler et al. 2008] . In rodents, E 2 increases the number of circulating EPCs and enhances their adherence and homing to the region of vascular damage. Likewise, in premenopausal women the number of circulating EPCs is synchronized with the menstrual cycle and is highest during the fertile period [Robb et al. 2009; Foresta et al. 2008 ]. Furthermore, EPCs in men reportedly showed a lower adherence capacity than those in premenopausal women, an effect that was abolished by E 2 supplementation [Fadini et al. 2008] . In this context, a recent study [Lan Shang Leen et al. 2008] has provided clear evidence for positioning osteopontin (OPN) downstream of E 2 /estrogen receptor (ER) a-signaling with an unprecedented role for OPN in the homing of EPCs to the region of vascular damage. They postulated possible mechanisms of estrogen-induced OPNdependent EPC homing to sites of vascular injury. OPN and OPN-fragments (OPN frag) likely serve as linkers between EPCs and vasvcular endothelium through their capacity to bind to integrins and CD44. Osteoblasts and EPCs as well as vascular cells serve as the source for OPN. Estrogen (E 2 ) might stimulate this OPNdependent homing of EPCs through modification of EPC-differentiation (mod EPC) in the bone marrow compartment; for instance by increasing the expression of VEGF-R2 or by stimulating the production by OPN and subsequent release of OPN by residing osteoblasts. Estrogen also might stimulate the production of OPNfragments through stimulation of matrix metalloproteinase (MMP) activity, increasing the binding capacity of the modified EPC to the injured vessel wall.
From these developments, the concept of arterial wall repair mediated by basement membrane (BM)-derived EPCs was born, providing an alternative to the local 'response to injury hypothesis' for the development of atherosclerotic inflammation (Figure 1 ) ]. According to this new theory, the arterial wall can handle multiple circulating and local noxious stimuli, as long as the BM-derived repair capacity, which includes competent EPCs, is functioning properly. Senescence of selected BM pathways, a process that is accelerated by the passage of time in the presence of risk factors, can lead to the inability of the BM to produce repair-competent EPCs [Rauscher et al. 2003; Edelberg et al. 2002] . Thus, exogenous cells from young, but not old, BMs have the ability to engraft and rejuvenate arterial intimal cells in mouse models of atherosclerosis, as evidenced by the elongation of the telomeres of these cells [Serrano and Andres, 2004; Rauscher et al. 2003; Chang and Harley, 1995] . The lack of ability of aging organisms to renew EPCs exposed to noxious stimuli leads to endothelial dysfunction and the consequent genesis of atherosclerosis.
Transplantation of BM-derived mononuclear cells (BMCs) into ischemic tissues has been shown to improve perfusion in young mice (8 weeks); however, the effect is markedly weaker when BMCs from older animals (18 months) are used [Sugihara et al. 2007 ]. Heeschen et al. [2004] transplanted BMCs into ischemic hindlimbs of nude mice and found that the recovery of blood flow was significantly impaired in the group treated with BMCs from subjects with coronary artery disease (CAD) compared with those that received BMCs from healthy subjects. Likewise, incorporation of BMCs from subjects with CAD into the vascular structures of the ischemic limbs was markedly reduced. Consistent with the results of animal studies, recent clinical trials have reported limited benefits of autologous cell therapy in CAD patients [Ward et al. 2007 ]. Conversely, age-associated impairment of cardiac angiogenesis in mice can be reversed by implantation of BM-derived EPCs from young animals [Edelberg et al. 2002] . Moreover, chronic treatment with BM-derived EPCs from young mice deficient in apolipoprotein E (apoE) prevents the progression of atherosclerosis in apoE-deficient recipients; however, the effectiveness of this therapy is reduced when the donor is older [Edelberg et al. 2002] . In apoE-deficient recipients, this treatment appears to prevent endothelial senescence and vascular inflammation, because analysis of treated animals shows that they have longer telomeres in their vascular cells and lower plasma levels of cytokine. These results suggest that age-associated deterioration of EPCs contributes to the impairment of vascular repair in elderly subjects, thereby increasing the morbidity caused by cardiovascular disease. This impairment must be considered when elderly patients are treated with autologous EPCs.
The number of circulating EPCs in patients with coronary artery disease has been shown to decrease with age. Aside from changes in EPC levels, the function of EPCs from older individuals also appears to be disrupted, as determined by in vitro examination of EPC survival, proliferation and migration [Imanishi et al. 2008 ]. These results strongly suggest that age is an important determinant of EPC function and further support the hypothesis that changes in EPC function with age contribute to the impairment of cardiovascular repair mechanisms in the aging host. Because the repair process originating from the Figure 1 . Effect of bone marrow obsolescence on cardiovascular repair. Competent bone marrow capable of producing the type of progenitor cells for cardiovascular repair (young marrow), inflammatory cytokines, growth factors, and other agonists contributes to the recruitment of repair cells. Once the cardiovascular lesion is repaired successfully, the inflammatory markers subside (negative feedback loop). In contrast, if the bone marrow is unable to produce these progenitor cells, either because the pathways that are required for their production are deficient or because the produced cells are somehow incompetent, the inflammatory factors contribute to atherosclerosis, essentially indicating a persistent cardiovascular lesion. The increase in inflammatory factors, in turn, can cause further cardiovascular damage, with worsening of the cardiovascular lesion.
BM is induced by cytokines, growth factors, and other proinflammatory elements (such as monocyte inflammatory peptide-1-alpha, monocyte chemotactic protein-1, interleukin 1-beta, interleukin-6, tumor necrosis factor-alpha, C-reactive protein, and interferon-gamma), a delinquent repair process can lead to progressive amplification of the inflammatory signals owing to the lack of a negative feedback loop [Ballard and Edelberg, 2007] . These signals in turn contribute to the aggravated inflammatory reaction (Th2predominant), further damaging the arterial wall (positive feedback loop) [Wassmann et al. 2006; Ali et al. 1997 ]. Hence, the elevated levels of markers not only reflect the intensity of atherosclerotic inflammation but may also identify individuals whose arterial repair is insufficient.
The age-associated impairment of EPC mobilization and function may be related to changes in NO and reactive oxygen species (ROS). Specifically, eNOS expression and subsequent NO production are critical in EPC mobilization [Matsushita et al. 2001] . Indeed, eNOS is a central downstream mediator in the VEGF and estrogen-signaling pathways [Bernardini et al. 2005; Lantin-Hermoso et al. 1997; Papapetropoulos et al. 1997 ]. Moreover, oxidized low-density lipoprotein (ox-LDL), which accumulates with age, also suppresses eNOS expression and impairs EPC survival and function [Ma et al. 2006 ]. Hypercholesterolemia, a risk factor for CVD, is linked to decreased circulating levels of EPCs in humans as well as depressed function of EPCs in vitro, and is associated with impaired cell migration, proliferation and vasculogenic activity [Chen et al. 2004] . Identifying factors that are downregulated with age and that are essential for the maintenance of progenitor cell number and function may, therefore, provide novel targets for the restoration of cardiovascular repair mechanisms in older individuals. Fadini et al. [2008] have investigated to assess the relationships between EPCs, gender, reproductive state, and cardiovascular profile. As measured by flow-cytometry in 210 healthy subjects, CD34 + KDR + EPCs were higher in fertile women than in men, but were not different between postmenopausal women and agematched men. These gender gradients mirrored difference in cardiovascular profile, carotid intima-media thickness, and brachial artery flow-mediated dilation. Moreover, EPCs and soluble c-kit ligand varied in phase with menstrual cycle in ovulatory women, suggesting cyclic bone marrow mobilization. EPCs cultured from female healthy donors were more clonogenic and adherent than male EPCs. Treatment with E 2 stimulated EPC proliferation and adhesion via estrogen receptors. Moreover, they showed that the proangiogenic potential of female EPCs were higher than that of male EPCs in vivo.
Gender differences in EPCs
In accordance with these findings, in a healthy middle-aged population without known cardiovascular risk factors, it has been demonstrated that women exhibited a distinctly higher EPC colony-forming capacity (approximately 150%) and greater migratory activity (40%) compared with men [Fadini et al. 2008] . Moreover, human women with a higher plasma estrogen concentration showed a significantly higher level of circulating EPCs. Increase in the number of EPCs by E 2 is mediated by decreased rate of apoptosis through a caspase-8-dependent pathway [Iwakura et al. 2003 ]. However, another similar study failed to demonstrate significant gender specific differences in the frequency of colony formation [Hoetzer et al. 2007 ].
Regarding male sex hormone effects, recent clinical studies suggest that androgens increase the number of circulating EPCs through a possible effect on bone marrow. It has been revealed that hypogonadotrophic hypogonadal men have low circulating EPCs that increase significantly after androgen treatment [Foresta et al. 2006] . A direct effect of testosterone also was suggested by expression of androgen receptor (AR) mRNA and protein in human EPCs. Synthetic androgen, methyltrienolone (RI881), causes AR translocation in the nucleus, suggesting its activation increases proliferation, migration and colony formation activity of these cells. Proliferation, migration and colony formation activities of the EPCs could be abolished by pretreatment with flutamide [Foresta et al. 2007] . A greater understanding of these molecular mechanisms will yield insights into how gender differences affect the healing process in patients.
Effects of estrogen on early and late EPCs
Considering the growing importance of the EPCs in cardiovascular research, it is crucial to investigate the characteristics of the EPCs in detail. There are at least two morphological and functionally distinct EPCs. The early EPCs possess a Therapeutic Advances in Cardiovascular Disease 4 (1) relatively low proliferative capacity and low ability to express mature endothelial proteins [Hur et al. 2004 ]. These cells presumably represent cells of different lineage, which include a subset of CD14 + /CD34 À monocytic cells, which have the potential to differentiate (transdifferentiate) into endothelial-like cells under certain environmental conditions in the presence of special growth factors (e.g. VEGF and fibroblast growth factor) [Urbich et al. 2003 ]. Late EPCs show a high proliferative potential and originate predominantly from BM donors and are considered as circulating angioblasts. Therefore, the effects of sex hormones on early and late EPCs should be discussed separately. Fadini et al. [2009] have demonstrated that treatment with E 2 stimulated late EPC proliferation and adhesion via estrogen receptors. They also found that late EPCs cultured from female healthy donors were more clonogenic and adherent than male EPCs. In addition, after menopause, on cessation of both ovarian and endometrial function, female EPCs decrease to the levels of coeval males, thus hampering vascular homeostasis and increasing cardiovascular risk. These results contradict a study showing that, in comparison with men, postmenopausal women had higher early EPCs, which is now known to select a subpopulation of monocytes/macrophages instead of endothelial cells. Interestingly, testosterone and its active metabolite exert no effect on expansion and function of late EPCs isolated from peripheral blood healthy human adult males, while they positively modulate early EPCs [Fadini et al. 2009 ].
Function and antioxidative capacity of EPCs
Antioxidant enzymes reduce the levels of intracellular ROS under physiological conditions. Intracellular superoxide dismutases (MnSOD and Cu/ZnSOD) are major antioxidant enzymes that catalyze the dismutation of superoxide anion (O À 2 ) to H 2 O 2 . H 2 O 2 in turn is further degraded into H 2 O and O 2 by catalase and glutathione peroxidase (GPx-1). Recently, two in vitro studies have demonstrated that EPCs express higher levels of manganese superoxide dismutase (MnSOD) and glutathione peroxidase-1 (GPx-1) [Dernbach et al. 2004; Blokhina et al. 2003 ]. It has also been shown that the collective inhibition of catalase, MnSOD, and GPx-1 increases ROS level in EPCs and that this inhibition impairs the survival and migration of EPCs [He et al. 2004 ]. In fact, some studies have suggested that EPCs may be resistant to oxidative stress [He et al. 2004; Dernbach et al. 2004 ]. Interestingly, EPCs have higher levels of both MnSOD and GPx-1 compared to human umbilical vein endothelial cells (HUVECs) and adult microvascular endothelial cells (ECs), which suggest that EPCs have higher antioxidant expression compared to HUVECs and adult ECs. Dernbach et al. [2004] reported that EPCs are resistant to oxidative stress and uniquely equipped to repair damaged vessels in ischemic tissues. However, some controversies do exist regarding the effects of oxidative stress on EPCs. Ingram et al. [2007] reported that EPCs showed increased apoptosis and diminished tubeforming ability in vitro and in vivo in response to oxidative stress, which was directly linked to the activation of a redox-dependent stress-induced kinase pathway. Galasso et al. [2006] investigated ischemia-induced neovascularization in GPx-1deficient mice and assessed the number and functional activity of EPCs. GPx-1-deficient mice showed a reduced recovery of blood flow after hindlimb ischemia compared with their wild-type littermates. This was accompanied by reduced EPC level in response to ischemic injury or to VEGF administration, and a reduction of the functional capacity of EPCs to migrate and promote angiogenesis in vitro. This study supports the theory that EPCs require antioxidative enzymes, specifically GPx-1, for their functional capacity. The finding that GPx-1 expression is essential for EPC function may also have clinical implications, given that patients with chronic heart failure [Linke et al. 2005] and type 2 diabetes [Colak et al. 2005] showed GPx-1 downregulation. This, in turn, may contribute to the reduced number and function of EPCs in patients with coronary artery disease and severe heart failure [Valgimigli et al. 2004; Vasa et al. 2001b ]. However, other antioxidative enzymes, such as superoxide dismutase and catalases, are also downregulated in these patients [Colak et al. 2005; Linke et al. 2005 ].
Thus, it appears mandatory to understand the specific role of various antioxidative enzymes in EPC function. In the future, specifically interfering with the expression and activity of antioxidative enzymes in progenitor cells from patients might be a therapeutic strategy to improve their regenerative potential.
Effects of estrogen on angiotensin II-induced acceleration of senescence Angiotensin II (Ang II) increases oxidative stress and inflammation, and alters endothelial function [Touyz, 2004; Sowers, 2002] . The principle source of ROS in the human vasculature is NAD(P)H oxidase, which is activated by a number of proatherogenic stimuli including Ang II. Several components contribute to the overall NAD(P)H oxidase activity in cells. These include cell-membrane-associated p22phox and gp91phox (or gp91phox [nox2] homologues, nox1 and nox4), as well as cytosolic p47phox and p67phox [Lassegue and Clempus, 2003] . Vascular NAD(P)H oxidase is upregulated by vasoactive factors, stretch, shear stress, and pulsatile strain [Lassegue and Clempus, 2003] . At low concentrations, ROS serve a physiological role as signaling molecules involved in endothelial function and vascular contractility [Vasa et al. 2001 ]. However, pathological increases in ROS result in a plethora of effects that damage the vessel wall [Lassegue and Clempus, 2003 ].
We previously showed that, in animal models of hypertension as well as in patients with essential hypertension, EPCs become precociously senescent and dysfunctional [Imanishi et al. 2005b] . Higher blood pressure is associated with lower numbers of EPCs in the general population [Fadini et al. 2006 ]. Hyper-reactivity of the reninangiotensin system (RAS) has been recognized as one link between hypertension and the altered biology of EPCs. Accumulating findings suggest that Ang II accelerates the onset of EPC senescence by increasing oxidative stress in patients with hypertension. Subjects who were treated with RAS inhibitors had an increased number of EPCs. Bahlmann et al. [2005] showed that the Ang II-receptor antagonist olmesartan increases the number of EPCs in prospective studies in prospective studies in normotensive and moderate hypertensive individuals. Similarly, Min et al. [2004] showed that a large number of EPCs could be cultured from ramipri-treated patients (rampiri is an angiotensin-converting enzyme [ACE] inhibitor) with stable CAD and that ACE inhibition resulted in improved functional properties such as adhesion, proliferation, migration, and in vitro vasculogenesis, independently of any impact of blood pressure. These findings support the important role of RAS in regulation of EPC bioavailability in patients with hypertension and CAD.
Our group showed that Ang II increases the rate of EPC senescence and that this appears to be a consequence of its ability to stimulate gp91phox expression and thus O À 2 formation [Imanishi et al. 2005c ]. In addition, we demonstrated that the ability of Ang II to induce senescence also involves telomerase suppression. Our group also observed an expected increase in the formation of a marker of oxidative stress, peroxynitrite, which is formed from O À 2 and NO in the Ang II-treated EPCs. Increased O À 2 production is a feature of Ang II-dependent hypertension [Heitzer et al. 1999 ]. Thus, under conditions of Ang II excess, Ang II possibly contributes to the decrease in the formation of the vascular endothelium, at least in part by the mechanisms of Ang II-induced EPC senescence (Figure 2 ). On the other hand, it has been demonstrated that Ang II and angiotensin peptides promote hematopoietic progenitor cell proliferation and hematopoietic recovery after radiation therapy and chemotherapy [Rodgers et al. 2000 ]. The Ang II-AT1 receptor pathway plays an important role in angiogenesis associated with ischemia and tumor growth [Egami et al. 2003; Sasaki et al. 2002] . These results appear to be contradictory to the protective effects of (ROS) suppression on EPC function. Recent studies have suggested that the intracellular redox state is a critical modulator of the balance between self-renewal and differentiation in dividing precursor cells and that antioxidants may preserve their stemness [Noble et al. 2003 ].
Regarding the interaction between estrogen and Ang II, we showed that estrogen inhibits Ang IIstimulated oxidative stress and reduces Ang IIinduced acceleration of EPC senescence, at least in part through AT 1 R downregulation ( Figure 2) [Imanishi et al. 2005d] . It is intriguing that our EPC data demonstrated an Ang II-induced increase in AT 1 R. One possible explanation may be that greater production of peroxynitrite ROS attributable to Ang II leads to the activation of nuclear factor kB (NFkB) to upregulate AT 1 R, as demonstrated by other cell types [Li et al. 2000; Ichiki et al. 1998 ]. Indeed, Gragasin et al. [2003] have shown that Ang II stimulates a significant increase in AT 1 R expression in bovine coronary microvascular endothelial cells. Morever, it has been suggested that NFkB activation is important in the upregulation of AT 1 R expression. Because NFkB is redox-sensitive, an increase in oxidative stress would activate this transcription factor and increase AT 1 R expression [Ruiz-Ortega et al. 2000 ]. Furthermore, Cooke and Davidge [2002] have demonstrated that peroxynitrite activates NFkB. We also previously showed that E 2 significantly inhibited Ang II-induced activation of mitogen-activated protein kinases (MAPKs), although E 2 had no significant effect on the phosphorylation of ERK1/2 and p38 MAPK [Imanishi et al. 2005d ]. Taking these findings together, it appears that the inhibitory effect of estrogen on Ang II-induced senescence may be partially the result of AT 1 R downregulation induced by estrogen. However, the prevention of Ang II-mediated responses by estrogen may involve other effects, such as direct effects on the senescence process. In postmenopausal women, there may be an exaggerated response to Ang II attributable to an increase in AT 1 R expression due to age and lack of E 2 because it has been suggested that this receptor subtype is upregulated with age [Touyz et al. 1999] . Therefore, another cardioprotective role of E 2 may be its interaction with AT 1 R. Indeed, a decrease in the Ang II response induced by a decrease in AT 1 R expression would attenuate the stimulation of superoxide anion production and peroxynitrite formation. Very recently, Sanada et al. [2009] have shown that hepatocyte growth factor, but not VEGF, attenuates Ang II-induced senescence of EPCs through a reduction of oxidative stress by inhibition of the PIP3/rac1 pathway.
Effect of estrogen on EPC senescence
Recent insights suggest that the injured endothelial monolayer is repaired by circulating bone marrow-derived endothelial progenitor cells (BM-EPCs), which accelerate re-endotheliazation and limit atherosclerotic lesion formation. This beneficial property of BM-EPCs makes them attractive targets for influencing the regeneration of ischemic tissue. BM-EPCs are not pluripotent, self-renewing stem cells, but rather lineage-committed progenitors, and are thus subject to a Hayflick lifespan via replicative senescence [Hayflik and Moorhead, 1961] . Therefore, an important question with respect to potential cell therapeutic approaches is whether the endogenous BM-EPC pool can be Figure 2 . Potential mechanisms of protective effects of estrogen on Ang II-induced EPC senescence. Ang II stimulates the expression of gp91phox, a subunit of NADPH oxidase, via the angiotensin type 1 (AT 1 ) receptor, which leads to the increase in superoxide (O À 2 ). Furthermore, peroxynitrite is formed from the interaction of O À 2 with nitric oxide (NO). Both superoxide and peroxynitrite inactivate telomerase activity, which induces the impairment of telomere structure integrity, resulting in senescence. On the other hand, estrogen, under Ang II stimulation, downregulates AT 1 receptor expression, which leads to a decrease in oxidative stress and an increase in telomerase activity resulting in the prevention of EPC senescence.
revitalized in vivo with pharmacological agents, cytokines, or even gene therapy.
Studies of telomerase regulation in normal somatic cells have focused on expression of the two essential components of telomerase, telomerase RNA template (hTER) [Feng et al. 1995] and hTERT [Nakamura et al. 1997 ]. There is a good correlation between the expression of hTERT mRNA and the presence of telomerase activity in extracts from tissue culture cells and normal and cancer tissues [Geider, 1998] ; whereas hTER is expressed constitutively in both cancer and normal cells, irrespective of the status of telomerase expression [Feng et al. 1995] . Interestingly, Murasawa et al. [2002] have revealed that hTERT overexpression by adenovirus-mediated gene delivery could result in the delay of senescence and the recovery/enhancement of the regenerative properties of EPCs.
Both human and animal studies have revealed higher telomerase activity and a diminished rate of age-related telomere ablation resulting in longer telomeres in females than in males [Nawrot et al. 2004; Cherif II et al. 2003; Benetos et al. 2001; Jeanclos et al. 2000; Leri et al. 2000; Coviello-McLaughlin et al. 1997 ]. Estrogen may indirectly exert a protective effect on telomeres because of its antioxidant properties [Mooradian et al. 1993] . Moreover, evidence for direct effects of estrogens on telomerase activity has been provided both in vitro and in vivo. First, telomere activity in the endothelium varies across the menstrual cycle. Endometrial telomerase activity is negligible during menstruation but increases during the follicular phase, reaches maximum levels immediately before ovulation coinciding with a peak in estrogen levels and proliferative activity, and then falls during the luteal phase [Tanaka et al. 1998 ]. Notably, postmenopausal endometria and endometria from women treated with antiestrogens exhibit decreased telomerase activity. Second, estrogens induce TERT transcription in MCF-7 cells via an estrogen response element within the TERT promoter [Kyo et al. 1999 ] and activate the phosphatidylinositol 3-kinase(PI3-K)/Akt pathway in human ECs [Simoncini et al. 2000] , which in turn enhances human telomerase activity through hTERT phosphorylation [Kang et al. 1999 ]. Raloxifene, a selective estrogen receptor modulator, also upregulates telomerase activity in human umbilical ECs [Doshida et al. 2006 ]. Furthermore, estrogen stimulates the production of NO in vascular ECs [Simoncini et al. 2000 ], which also induces telomerase activity and delays EC senescence [Vasa et al. 2000] .
Increased blood estrogen level in women correlates with the number of circulating EPCs [Iwakura et al. 2003 ]. In an animal carotid injury model, E 2 treatment showed stimulatory effects on EPC mobilization, proliferation, and mitogenic and migratory activity, as well as inhibited apoptosis of EPCs [Iwakura et al. 2003 ]. Mechanistically, we demonstrated that estrogen augments differentiation and delays the onset of senescence in BM-EPCs from SHR/Izm, accompanied by telomerase activation via the upregulation of hTERT mRNA in a PI3-K/Aktdependent manner [Imanishi et al. 2005a ]. Importantly, the inhibition of BM-EPC senescence by estrogen in vitro resulted in improved functional activity of the BM-EPCs. We showed that E 2 inhibited the senescence of cultured human PB-MNCs in a dose-dependent manner by increasing the catalytic activity of telomerase [Imanishi et al. 2005a ]. Furthermore, we showed that this activation is accompanied by upregulation of the hTERT mRNA (Figure 3) [Imanishi et al. 2005a] . We speculated that estrogen delays the onset of senescence through telomerase activation, which may be related to estrogen-induced upregulation of the expression of hTERT. However, with regard to senescence, the structure of the telomere appears to be at least as important as its absolute length in relation to telomere function (Figure 3) [Matsumori et al. 2003 ]. In addition, we cannot rule out the possibility that a telomere-independent mechanism regulates replicative senescence. Further studies are required to elucidate the mechanisms underlying the inhibitory effects of E 2 on senescence in EPCs. Importantly, the inhibitory effects of E 2 on EPC senescence may not be of a beneficial nature only. Telomere shortening is possibly one of the body's anticancer mechanisms, and estrogen is considered to be a potentially cancer-promoting substance. Indeed, estrogens increase the incidence of various malignancies [Hulley et al. 2002] . It is tempting to speculate that the induction of neoplasia during estrogen treatment might be dependent on the effects of EPCs. On the other hand, the use of synthetic selective estrogen modulators (SERMs); for example, raloxifene and tamoxifen, could be viable alternative treatments to increase EPC function during aging without increased incidence of other E 2 -induced malignancies; for example, breast cancer.
Estrogen receptors and EPCs
Estrogen exerts multifaceted effects on the heart and blood vessels via genomic and nongenomic actions. The genomic action is slower in onset and is mediated via two estrogen receptors (ERs), ERa and ERb [Miller and Duckles, 2008] . Both ERa and ERb are expressed in endothelium, vascular smooth muscle cells, and cardiomyocytes [Shearman et al. 2003 ]. To explore sex hormone specificity in EPCs, ERa KO mice were treated with E 2 , which failed to induce migration, tube formation, adhesion and estrogen-responsive element-dependent gene transcription activities [Hamada et al. 2006 ]. Using a murine ischemic heart model, it also was shown that migration of EPCs into the ischemic border zone was impaired in ERa KO bone marrow transplant mice [Hamada et al. 2006 ]. Downregulation of VEGF also was noted in EPCs from ERa KO mice both in vivo and in vitro. The authors described that ERa expressed in EPCs plays a more potent role in pathological vasculogenesis, rather than ERb. Masuda et al. [2007] have also provided evidence that the physiologic cycle of estrogen regulates EPC kinetics; that is, differentiation, proliferation, migration, apoptosis, mobilization, and ultimately incorporation into foci of neovascularization in the developling endothelium. Recent studies demonstrated that E 2 activation of PI3-K/Akt and eNOS activation occurs through nongenomic mechanisms leading to the increased hTERT activation and function of EPCs as previously described [Imanishi et al. 2005a] . Iwakura et al. [2003] demonstrated that estradiol exerts cardioprotective effects in the setting of acute mayocardial infarction (MI) in mice by augmented mobilization and homing of EPCs and enhanced angiogenesis, resulting in improved cardiac function. More recently, Hamada et al. [2006] have identified differential roles of the two ERs in these phenomena. In vitro, the effects of estradiol on migration, proliferation, and tube formation by EPCs were severely impaired in EPCs from ERa À/À mice, whereas they were moderately attenuated in EPCs from ERb À/À mice. In vivo, both the mobilization of endogenous Sca-1 + /Flk-1 + EPCs after myocardial infarction (MI) and the homing of exogenous EPCs to the infarct border zone after estradiol treatment were significantly greater in wild-type (WT) mice than in WT recipients of ERa À/À and ERb À/À marrow. Consistent with these findings, WT recipients of ERa À/À and ERb À/À marrow exhibited lower capillary density in the border zone of the infarct and worse left ventricular function. The absence of ERa had a consistently greater impact on the end points of these experiments than did the absence of ERb. Furthermore, EPCs were found to express greater amounts of ERa mRNA and bind estradiol in a predominantly ERa-dependent manner. Interestingly, the expression of vascular endothelial growth factor in EPCs was significantly downregulated in the absence of ERa.
Regarding the relationship between the two ERs and the biology of EPCs, future studies should address several points. First, it appears important to investigate whether the number of circulating EPCs in patients with variants of ERa correlates with the incidence of adverse cardiovascular events. Second, given the beneficial effects of estradiol-induced mobilization of BM cells on cardiac function, should estradiol be administered after acute MI, especially in postmenopausal women? The answer to this question appears to be rather complicated. Hormone replacement therapy (HRT) in postmenopausal women was the accepted standard of care for many years until a randomized clinical trial showed that HRT actually increased the risk for cardiac events [Hulley et al. 1998 ]. Several other studies have since reported either no benefit or deleterious effects of HRT on cardiovascular outcomes. In the specific setting of acute MI, however, there is evidence that HRT may improve mortality [Splipak et al. 2001] . A better understanding of estrogen signaling via specific ERs and future clinical studies with estrogen therapy alone may conceivably produce a therapeutic paradigm shift. Third, a growing body of evidence suggests that estrogen favorably modulates endothelial function after coronary stenting [Khan et al. 2000 ]. If this beneficial effect is influenced by the ER expression pattern on human ECs, selective ER modulation may be used to improve outcomes after stenting. Finally, because premenopausal women appear to be protected from upregulated ERa and downregulated ERb expression in endothelial cells [Ihionkhan et al. 2002] , it will be interesting to determine whether gender-dependent differences in the effects of ER expression on EPCs (i.e., greater expression of ERa in women versus men) contribute to estrogen-related protection from cardiovascular events in premenopausal women.
These findings have clinical implications for understanding the relative roles of the two ERs in cardiovascular homeostasis and exploring the potential role of selective ER modulators in cardiac as well as vascular repair. Further studies are necessary carry out the following: (1) to investigate whether the ER-mediated beneficial effects of estradiol on postinfarction remodeling and function also involve other BM cells, (2) to decipher the molecular events whereby estradiol mobilizes EPCs, and (3) to determine the mechanism whereby these EPCs home to the infarcted myocardium in an ER-dependent fashion.
Aging, estrogen and EPCs Very recently, Kushner et al. [2009] demonstrated an age-related reduction in telomere length in adult humans. That is, they have shown that telomere length of circulating EPCs decline with age in healthy sedentary men. They also found that the onset of decline appears to be after the age of 55 years. On the other hand, estrogen has been shown to affect both circulating EPCs number and function [Stehlow et al. 2003 ] and previous studies have shown, in a variety of cell types, that women exhibit less agedependent telomere erosion than men [Cherif et al. 2003 ]. Thus, the onset and magnitude of decline in EPCs telomere length observed in men may differ in women. Further studies are needed to determine whether the reduction in telomere length contributes mechanistically to EPCs dysfunction in women and older adults.
Conclusions and implications
Recent data show that the vascular regenerative potential of patients with cardiovascular risk factors may be impaired as a consequence of the reduced number and function of circulating EPCs that can support endothelial maintenance and ischemia-induced neovascularization. Recent studies have demonstrated a critical role of oxidative stress in EPC dysfunction. Notably, oxidative stress-induced premature senescence of EPCs is involved in this process. Autologous transplantation of progenitor cells that are affected by cardiovascular risk factors may not only be hampered by the dysfunctional nature of these cells but in fact may also stimulate proatherogenic mechanisms, such as monocyte recruitment or vascular smooth muscle cell proliferation. Therefore, attention should be paid during transplantation of autologous BM cells or circulating EPCs not to promote atherosclerosis. The therapeutic goal must be the rebalancing of endothelial injury and repair processes. In the future, the use of a vascular repair index may be an important aid for choosing therapy strategies with a maximized benefit for the patient. In this context, it is noted that estrogen delays the onset of senescence in EPCs, which may be related to telomerase activation. The inhibition senescence in EPCs by estrogen in vitro may improve their functional activity in a way that is important for potential cell therapy. With this knowledge in mind, we need to search for more effective regenerative therapeutic strategies not only for neoangiogenesis but, more importantly, for the regeneration of the dysfunctional vascular wall, which represents the common trunk for all cardiovascular diseases. 
